DiMango Emily, Holbrook Janet T, Simpson Erin, Reibman Joan, Richter Joel, Narula Surinder, Prusakowski Nancy, Mastronarde John G, Wise Robert A
Columbia University, College of Physicians and Surgeons, New York, New York, USA.
Am J Respir Crit Care Med. 2009 Nov 1;180(9):809-16. doi: 10.1164/rccm.200904-0625OC. Epub 2009 Aug 6.
Silent gastroesophageal reflux (GER) is common in patients with asthma, but it is unclear whether GER is associated with worse asthma symptoms or reduced lung function.
To determine in patients with poorly controlled asthma, whether proximal or distal esophageal reflux is associated with asthma severity, symptoms, physiology, or functional status.
Baseline asthma characteristics were measured in patients with asthma enrolled in a multicenter trial assessing the effectiveness of esomeprazole on asthma control. All participants underwent 24-hour esophageal pH probe monitoring. Lung function, methacholine responsiveness, asthma symptoms, and quality-of-life scores were compared in subjects with and without GER.
Of 304 participants with probe recordings, 53% had reflux. Of 242 participants with recordings of proximal pH, 38% had proximal reflux. There was no difference in need for short-acting bronchodilators, nocturnal awakenings, dose of inhaled corticosteroid, use of long-acting beta-agonists, lung function, or methacholine reactivity between individuals with and without proximal or distal GER. Participants with GER reported more use of oral corticosteroids and had worse asthma quality of life and subjects with proximal GER had significantly worse asthma quality of life and health-related quality of life compared with participants without GER.
Asymptomatic GER is not associated with distinguishing asthma symptoms or lower lung function in individuals with suboptimal asthma control who are using inhaled corticosteroids. Patients with proximal reflux report significantly worse asthma and health-related quality of life despite lack of physiologic impairment or increase in asthma symptoms. Clinical trial registered with www.clinicaltrials.gov (NCT00069823).
无症状性胃食管反流(GER)在哮喘患者中很常见,但尚不清楚GER是否与更严重的哮喘症状或肺功能下降有关。
确定在哮喘控制不佳的患者中,食管近端或远端反流是否与哮喘严重程度、症状、生理状况或功能状态相关。
在一项评估埃索美拉唑对哮喘控制效果的多中心试验中,对入选的哮喘患者测量其基线哮喘特征。所有参与者均接受24小时食管pH探头监测。比较有无GER的受试者的肺功能、乙酰甲胆碱反应性、哮喘症状和生活质量评分。
在304名有探头记录的参与者中,53%有反流。在242名有近端pH记录的参与者中,38%有近端反流。有无近端或远端GER的个体在使用短效支气管扩张剂的需求、夜间觉醒次数、吸入性糖皮质激素剂量、长效β受体激动剂的使用、肺功能或乙酰甲胆碱反应性方面没有差异。与无GER的参与者相比,有GER的参与者报告口服糖皮质激素的使用更多,哮喘生活质量更差,有近端GER的受试者哮喘生活质量和健康相关生活质量明显更差。
在使用吸入性糖皮质激素且哮喘控制不佳的个体中,无症状性GER与哮喘症状的差异或肺功能降低无关。尽管没有生理损害或哮喘症状增加,但有近端反流的患者报告的哮喘和健康相关生活质量明显更差。临床试验已在www.clinicaltrials.gov注册(NCT00069823)。